阿托伐他汀对急性冠脉综合征患者血清中白介素18、基质金属蛋白酶2的影响

目的 探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清白介素18(IL-18)、基质金属蛋白酶2(MMP2)的影响.方法 ACS组86例,稳定性心绞痛组(SAP) 40例,冠状动脉造影正常者40例为对照组,按随机原则,将ACS患者划分为阿托伐他汀组和普通治疗组,每组各43例.酶联免疫吸附法(ELISA)测定样本血清IL-18、MMP2水平,比较各组血清IL-18、MMP2水平的变化.结果 ACS组患者血清IL-18、MMP2水平显著高于SAP组和对照组(P＜0.05).阿托伐他汀组治疗前后及普通治疗组治疗前后比较,血清IL-18、MMP2水平均明显下降(P＜0.05).结论 阿托伐他汀可降低ACS患者血清IL-18、MMP2水平,抑制冠状动脉粥样斑块炎症反应和基质成分的降解,促进粥样硬化斑块的稳定性,降低ACS的发生率.

Effect of Atorvastatin on Serum IL-18,MMP2 in Patients with Acute Coronary Syndrome

Objective To explore the effect of atorvastatin on serum levels of IL-18、MMP2 in patients with acute coronary syndrome(ACS).Methods ACS group(n=86)and stable angina pectoris(SAP)group(n=40).40 individuals with normal coronary angiography were selected as control group.At the same time,86 patients with ACS were randomly divided into atorvastatin group(n=43)and conventional-treated group(n=43).Serum levels of IL-18、MMP2 were measured by enzyme-linked immunosorbent assay(ELISA).The change of serum IL-18、MMP2 levels was compared among the groups.Results Serum levels of IL-18、MMP2 in ACS group were significantly higher than those in SAP group and control group(P<0.05).After the treatment,serum levels of IL-18、MMP2 in atorvastatin group and conventional-treated group were significantly decreased compared with those in the two groups before the treatment(P<0.05).Conclusion Atorvastatin can decrease serum IL-18、MMP2 levels in patients with ACS,which contributes to suppression of inflammation response and matrix degradation,to advance the stability of atherosclerosis plaque and lower the rate of acute coronary syndrome.